Genesoft Factive review
Executive Summary
Anti-Infectives Drugs Advisory Committee will review Genesoft's Factive (gemifloxacin) for community-acquired pneumonia and acute exacerbation of chronic bronchitis at its March 4 meeting. Factive received a "not approvable" letter from FDA in December 2000 under an application sponsored by SmithKline Beecham. Following its merger with Glaxo, GSK returned rights for Factive to LG Life Sciences, which then licensed the drug to South San Francisco-based Genesoft. The meetings will be held at the Marriott Washingtonian Center in Gaithersburg, Md. beginning at 8 a.m. on March 4 and 9 a.m. on March 5...
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.